Skip to main content

Table 4 Treatment-emergent adverse events (TEAEs)

From: Intranasal budesonide for rhinitis during a high airborne pollution period: a randomized controlled trial

TEAEs, n (%)

Budesonide

(N = 103)

Placebo

(N = 103)

Subjects with ≥ 1 TEAE

5 (4.9%)

8 (7.8%)

Upper respiratory tract infection

3 (2.9%)

3 (2.9%)

Pharyngitis

1 (1.0%)

0

Epistaxisa

0

1 (1.0%)

Nasal congestion

0

1 (1.0%)

Nasal discomforta

1 (1.0%)

0

Sneezinga

1 (1.0%)

0

Cupulolithiasis

0

1 (1.0%)

Headache

0

1 (1.0%)

Insomnia

0

1 (1.0%)

  1. aTreatment-related AEs